//

Xoma Ltd.

Posted Mon, 09/14/2009 - 13:03 by Zefu

Xoma Ltd.

2910 Seventh Street
Berkeley, CA 94710
USA
Phone: (510) 204-7200
Fax: (510) 644-0539
Email: investorrelations@xoma.com
Web Site: http://www.xoma.com/

A. Company Profile

Xoma (NASDAQ:XOMA) is a leader in discovery, development, and manufacture of therapeutic antibodies for multiple therapeutic targets, including cancer.

B. Products

Product Pipelines
Product Indication Clinical Status
HCD122 Mab Chronic lympnocytic leukemia and multiple myeloma Phase I

1. HCD122 Mab

HCD122 is a fully human, antagonist antibody that targets the CD40 antigen. HCD122 binds to tumor cells that express CD40 and antagonizes (prevents) CD40 ligand-mediated growth and survival of malignant B cells. HCD122 also induces antibody-dependent cellular cytotoxicity (ADCC), killing CD40 expressing tumor cells by immune effector cells. This dual mechanism of action makes HCD122 a drug candidate with potential for the treatment of B-cell malignancies.